Patents Assigned to Board of Trustees, Univ. of TX Sys.
  • Patent number: 5607924
    Abstract: Methods of cleavage of a polymer of deoxyribonucleic acid using photosensitive texaphyrins are disclosed. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 4, 1997
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Meredith Wright
  • Patent number: 5601802
    Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. These texaphyrin metal complexes having enhanced stability are useful for localization, magnetic resonance imaging, radiosensitization, radiation therapy, fluorescence imaging, photodynamic therapy, RNA hydrolysis, DNA photocleavage, and applications requiring singlet oxygen production for cytotoxicity. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 11, 1997
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
  • Patent number: 5595726
    Abstract: The present invention is directed to chromophoric probes for use in detecting nucleic acid sequences. More particularly, the invention is directed to probes that comprise a texaphyrin chromophore molecule covalently coupled or conjugated to a site-directing molecule, the site-directing molecule having affinity for a biological receptor or a nucleic acid sequence. In one embodiment of the invention, the probe comprises a texaphyrin chromophore conjugated to an oligonucleotide having complementary binding affinity for a target nucleic acid sequence.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 21, 1997
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent Iverson
  • Patent number: 5587371
    Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 24, 1996
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
  • Patent number: 5583220
    Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: December 10, 1996
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Jonathan L. Sessler, Anthony M. Harriman, Richard A. Miller, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral, Darren Magda